NRAS and colorectal carcinoma: Based on the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology Consensus, mutational analysis should include KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 of exon 3, and 117 and 146 of exon 4 (“expanded” or “extended” RAS)38 Moreover, this Consensus recommend BRAF p.V600 position mutational analysis in CRC tissue in selected patients with colorectal carcinoma for prognostic stratification, and also in dMMR tumors with loss of MLH1 to evaluate for Lynch syndrome risk.